Core Viewpoint - Nurix Therapeutics, Inc. successfully closed an underwritten registered offering of 24,485,799 shares at $10.21 per share, raising gross proceeds of $250 million to fund clinical development and research activities [1][4]. Group 1: Offering Details - The offering included participation from both new and existing investors, highlighting strong support for the company's mission [2]. - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [3]. - The securities were offered under a shelf registration statement previously filed with the SEC [5]. Group 2: Use of Proceeds - The net proceeds will primarily fund the clinical development of bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and explore potential autoimmune indications [4]. - Additional funds will support research and development activities to expand the pipeline and cover working capital and general corporate purposes [4]. Group 3: Company Overview - Nurix Therapeutics focuses on targeted protein degradation medicines for oncology and autoimmune diseases, with a pipeline that includes degraders of Bruton's tyrosine kinase (BTK) [8][9]. - The company is advancing multiple potentially first-in-class or best-in-class drug candidates and has collaborations with major pharmaceutical companies like Sanofi and Gilead [8][9].

Core Viewpoint - Nurix Therapeutics, Inc. has announced the pricing of its underwritten registered offering of 24,485,799 shares at $10.21 per share, aiming to raise approximately $250 million for clinical development and research activities [1][4]. Group 1: Offering Details - The offering consists of 24,485,799 shares priced at $10.21 each, with expected gross proceeds of $250 million before expenses [1]. - The offering is set to close on or about October 23, 2025, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as General Atlantic and Redmile Group [2]. Group 2: Use of Proceeds - Nurix intends to use the net proceeds primarily for clinical development of drug candidates, including bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and potential autoimmune indications [4]. - Additional uses include funding research and development to expand the pipeline, as well as for working capital and general corporate purposes [4]. Group 3: Management and Registration - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [3]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective on June 11, 2024 [5].

Core Viewpoint - Dynavax Technologies Corporation criticizes Deep Track Capital's investor presentation, asserting that it lacks understanding of the biotechnology sector and prioritizes short-term gains over long-term value creation [1][3]. Financial Performance - Dynavax reported total revenue of $68.2 million for Q1 2025, a 34% increase from $50.8 million in Q1 2024 [13]. - HEPLISAV-B® generated net product revenue of $65 million, marking a 36% increase compared to $47.8 million in Q1 2024 [13]. - The company expects to achieve full-year revenue guidance of $305 to $325 million [13]. - Adjusted EBITDA improved to negative $4 million from negative $7 million in Q1 2024, with expectations of at least $75 million in 2025 [13]. Strategic Direction - Dynavax emphasizes a balanced strategic plan that includes both internal and external growth opportunities while returning capital to stockholders [2][11]. - The company has executed over 85% of its $200 million share repurchase program, completing $172 million as of May 5, 2025 [13]. - Dynavax's market share for HEPLISAV-B® increased to approximately 43% from 41% in Q1 2024 [13]. Board and Governance - Dynavax urges stockholders to vote for its four director nominees, asserting that they possess superior qualifications compared to Deep Track's candidates [5][10]. - The current Board is described as highly qualified and refreshed, overseeing the company's successful strategic execution [4][11]. Growth Initiatives - Dynavax is advancing its differentiated vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant [8][9]. - New pipeline programs are being initiated alongside ongoing shingles and plague vaccine programs [8].

Core Viewpoint - Dynavax Technologies Corporation is urging stockholders to vote "FOR" its four director nominees in response to a proxy contest initiated by Deep Track Capital, emphasizing the company's strong financial performance and strategic direction [1][2][3] Financial Performance - Dynavax has achieved total stockholder returns of 267% over the past five years, significantly outperforming the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index [3][9] - The company reported a substantial increase in HEPLISAV-B® net product revenue, growing from $36 million in 2020 to a record $268 million in 2024, representing a 65% compound annual growth rate [9] - Anticipated net product revenue for HEPLISAV-B® in 2025 is projected to be between $305 million and $325 million, with expectations for the U.S. hepatitis B adult vaccine market to peak at over $900 million by 2030 [9] Strategic Direction - Dynavax is executing a disciplined capital allocation strategy, including a $200 million share repurchase program, of which $128.8 million has already been executed as of the end of Q1 2025 [8][9] - The company has refocused its portfolio on vaccines, successfully launching HEPLISAV-B® and advancing its differentiated vaccine pipeline [7][9] - Dynavax's board has been programmatically refreshed, with new directors possessing extensive experience in biotechnology and vaccine development [11][12] Governance and Board Composition - The board nominees proposed by Dynavax are described as highly qualified, with significant experience in the biotechnology sector, contrasting with the unqualified candidates put forth by Deep Track [3][15][18] - The board has implemented corporate governance enhancements, including a proposal to declassify the board, which aims to improve accountability and responsiveness to stockholders [12][19] Proxy Contest Context - Deep Track Capital is attempting to gain control of the Dynavax board to implement a short-term strategy that the company believes would be detrimental to long-term value creation [5][14][17] - Dynavax has made multiple attempts to reach a settlement with Deep Track to avoid a costly proxy contest, but these efforts have been met with resistance [16][17]